

Pierre Baumann

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5388593/pierre-baumann-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264 papers	9,197 citations	54 h-index	85 g-index
327 ext. papers	10,103 ext. citations	3.2 avg, IF	5.48 L-index

#	Paper	IF	Citations
264	Pharmacotherapy of Personality Disorders 2022 , 1-18		
263	Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major Depression. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 436-442	3.2	
262	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. <i>World Journal of Biological Psychiatry</i> , 2021 , 22, 561-628	3.8	3
261	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 79-102	3.2	9
260	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. <i>Journal of Clinical Psychiatry</i> , 2020 , 81, 19-24	4.6	39
259	The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020 , 126, 444-447	3.1	1
258	Guía de consenso de expertos para la monitorización terapéutica de drogas en neuropsicofarmacología. <i>Psiquiatría Biológica</i> , 2020 , 27, 83-95	0.2	0
257	Training in Psychopharmacology-Pharmacopsychiatry for Residents in Psychiatry. <i>Mental Health and Illness Worldwide</i> , 2019 , 141-167	0.1	
256	About the Misleading Use of Stereodescriptors in Labeling the Stereoisomers of Milnacipran and Levomilnacipran. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 673-674	1.7	
255	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 162-174	3.8	64
254	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018 , 51, 9-62	2	473
253	Training in Psychopharmacology-Pharmacopsychiatry for Residents in Psychiatry. <i>Mental Health and Illness Worldwide</i> , 2018 , 1-28	0.1	
252	A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 29-38	3.8	11
251	Age at the time of onset of psychosis: A marker of specific needs rather than a determinant of outcome?. <i>European Psychiatry</i> , 2017 , 45, 20-26	6	8
250	Clinical pharmacological management of polypharmacy in old age depression. <i>European Psychiatry</i> , 2016 , 33, S39-S39	6	
249	Consensus guideline for therapeutic drug monitoring in psychiatry (2004): Bibliometric analysis of citations for the period 2004-2011. <i>Nordic Journal of Psychiatry</i> , 2016 , 70, 202-7	2.3	
248	The AMSP-project: Pharmacovigilance in psychiatry - Presentation, challenges and results. <i>European Psychiatry</i> , 2014 , 29, 663-663	6	

247	Pharmacovigilance en psychiatrie : données récentes. <i>European Psychiatry</i> , 2014 , 29, 661-662	6	
246	A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. <i>Journal of Affective Disorders</i> , 2014 , 168, 269-75	6.6	70
245	CYP2D6: genetics, pharmacology and clinical relevance 2014 , 2-6		0
244	CYP2D6: clinical implications in neuropsychiatry 2014 , 134-150		
243	CYP2D6: Genetics, Pharmacology and Clinical Relevance 2014 ,		1
242	Therapeutic Drug Monitoring 2014 , 1-9		
241	Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. <i>Swiss Medical Weekly</i> , 2013 , 143, w13772	3.1	9
240	Central Nervous System Drugs 2012 , 301-329		1
239	Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial. <i>Psychiatric Quarterly</i> , 2012 , 83, 311-24	4.1	7
238	Flupentixol: relevance of stereoselective therapeutic drug monitoring. <i>Psychopharmacology</i> , 2012 , 221, 719-20	4.7	1
237	Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 622-9	1.7	21
236	Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. <i>International Journal of Neuropsychopharmacology</i> , 2012 , 15, 1051-61	5.8	25
235	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring 2012 , 441-464		4
234	JS01-01 - Pharmacokinetics of psychotropic drugs - keys for treatments' improvements. <i>European Psychiatry</i> , 2011 , 26, 1995-1995	6	
233	Therapeutic drug monitoring of drugs for treatment of substance-related disorders. <i>European Psychiatry</i> , 2011 , 26, 13-13	6	
232	Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza. <i>Psiquiatria Biologica</i> , 2011 , 18, 55-67	0.2	2
231	Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 561-72	3.2	20
230	Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. <i>Journal of Psychopharmacology</i> , 2011 , 25, 896-907	4.6	32

229	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. <i>Pharmacopsychiatry</i> , 2011 , 44, 195-235	2	641
228	Therapeutic drug monitoring in psychiatry. <i>Pharmacopsychiatry</i> , 2011 , 44, 193-4	2	
227	Quetiapine in adolescents with non-affective psychotic disorders: an open-label trial. <i>Pharmacopsychiatry</i> , 2011 , 44, 87-95	2	3
226	French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs. <i>Fundamental and Clinical Pharmacology</i> , 2010 , 24, 377-84	3.1	10
225	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents in the Drug Prescription Information. <i>International Journal of Knowledge Discovery in Bioinformatics</i> , 2010 , 1, 1-11		
224	Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with L- and D,L-methadone. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 390-9	3.8	13
223	Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 496-503	1.7	24
222	Are Proper Names Rigid Designators?. <i>Axiomathes</i> , 2010 , 20, 333-346	0.2	2
221	Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine. <i>Journal of Psychiatric Research</i> , 2010 , 44, 754-9	5.2	13
220	Pharmakokinetik 2010 , 289-351		
219	Cardiac left bundle branch block and pancytopenia in anorexia nervosa: higher risk with mirtazapine and pantoprazole? Case report. <i>Pharmacopsychiatry</i> , 2009 , 42, 79-81	2	12
218	Drug-induced Pisa syndrome under quetiapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009 , 33, 1286-7	5.5	20
217	Therapeutic Drug Monitoring and Pharmacogenetic Tests in Pharmacovigilance - When and What?. <i>European Psychiatry</i> , 2009 , 24, 1-1	6	
216	Steady-state concentrations of mirtazapine, N-desmethyilmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 63-70	6.2	35
215	Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. <i>European Neuropsychopharmacology</i> , 2009 , 19, 520-32	1.2	101
214	ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 319-26	1.7	98
213	Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. <i>Pharmacological Research</i> , 2008 , 58, 344-7	10.2	77
212	Pharmacovigilance in psychiatry: pharmacogenetic tests and therapeutic drug monitoring are promising tools. <i>Expert Review of Clinical Pharmacology</i> , 2008 , 1, 183-5	3.8	3

211	Effect of the NMDA-receptor antagonist dextromethorphan in infant rat pneumococcal meningitis. <i>Current Drug Metabolism</i> , 2008 , 9, 83-8	3.5	6
210	Concentrações plasmáticas de paroxetina em pacientes adultos e idosos com depressão. <i>Revista De Psiquiatria Do Rio Grande Do Sul</i> , 2008 , 30, 13-18		1
209	Increased creatinine kinase and rhabdomyolysis in anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2008 , 41, 766-7	6.3	9
208	Spezielle Arzneimittelinteraktionen 2008 , 1127-1144		2
207	Off-label utilization of antidepressants. <i>Acta Medica (Hradec Kralove)</i> , 2008 , 51, 19-24	0.8	0
206	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring 2008 , 375-397		1
205	Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007 , 11, 123-8	2.4	1
204	Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence. <i>Pharmacopsychiatry</i> , 2007 , 40, 121-7	2	19
203	Selective serotonin reuptake inhibitors in adolescent depression still controversial. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 325-6; author reply 326	1.7	1
202	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10 Suppl 1, S1-207	5.8	37
201	Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?. <i>Physiology and Behavior</i> , 2007 , 92, 226-31	3.5	46
200	Therapeutic drug monitoring of antidepressants [clinical aspects] 2007 , 261-267		9
199	Therapeutic drug monitoring of antidepressants--clinical aspects. <i>Journal of Neural Transmission Supplementum</i> , 2007 , 261-7		
198	Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. <i>Pharmacopsychiatry</i> , 2006 , 39, 150-2	2	13
197	Drug monographs on drugs which are frequently analysed in the context of Therapeutic Drug Monitoring / Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden. <i>Das Medizinische Laboratorium</i> , 2006 , 30, 443-452		
196	Mirtazapine enantiomers in blood and cerebrospinal fluid. <i>Neuropsychobiology</i> , 2006 , 54, 179-81	4	6
195	Dose-Dependent Venlafaxine-Induced Hair Loss. <i>Drug Safety</i> , 2006 , 29, 911-1010	5.1	
194	Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. <i>Drug Safety</i> , 2006 , 29, 735-68	5.1	64

193	Prevalence of substance use in a Swiss psychiatric hospital: interview reports and urine screening. <i>Addictive Behaviors</i> , 2006 , 31, 1252-8	4.2	28
192	Clinical relevance of TDM of SSRIs. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 716-7; author reply 717	3.2	5
191	Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 679-81	1.7	9
190	Psychotropic drug prescriptions in hospitalized elderly psychiatric patients: comparison with adult psychiatric patients. <i>Psychogeriatrics</i> , 2006 , 6, 68-73	1.8	
189	Treatment of suicide attempters prior to hospital admission. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005 , 29, 694-701	5.5	1
188	Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005 , 29, 952-6	5.5	18
187	Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 539-43	3.2	74
186	Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 593-604	6.1	184
185	Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005 , 60, 865-73	2.8	56
184	Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. <i>Psychopharmacology</i> , 2005 , 181, 751-60	4.7	78
183	Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. <i>International Journal of Neuropsychopharmacology</i> , 2005 , 8, 403-10	5.8	78
182	The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. <i>Dialogues in Clinical Neuroscience</i> , 2005 , 7, 231-47	5.7	38
181	Prescribing practices in German and Swiss psychiatric university and in non-university hospitals: national differences. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2005 , 43, 339-49	2	3
180	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , 2004 , 18, 559-66	4.6	5
179	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , 2004 , 18, 559-566	4.6	23
178	The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. <i>Pharmacopsychiatry</i> , 2004 , 37, 243-65	2	399
177	High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004 , 8, 191-5	2.4	4
176	Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. <i>European Journal of Clinical Pharmacology</i> , 2004 , 60, 237-46	2.8	74

175	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. <i>European Journal of Clinical Pharmacology</i> , 2004 , 60, 231-6	2.8	69
174	Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 802, 339-45	3.2	37
173	Determination of human plasma levels of levo-alpha-acetylmethadol and its metabolites by gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 805, 141-6	3.2	1
172	Death following acute poisoning by moclobemide. <i>Forensic Science International</i> , 2004 , 140, 101-7	2.6	11
171	Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 55-63	6.1	39
170	Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 214-9	1.7	83
169	High dose of depot risperidone in a nonresponder schizophrenic patient. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 673-4	1.7	13
168	Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 366-74	3.2	34
167	Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 283-90	1.7	27
166	CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 255-60		27
165	Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 152-5	3.2	21
164	Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 167-70	3.2	37
163	Methadone maintenance treatment and St. John's Wort - a case report. <i>Pharmacopsychiatry</i> , 2003 , 36, 35-7	2	68
162	Clinical outcome after trimipramine in patients with delusional depression - a pilot study. <i>Pharmacopsychiatry</i> , 2003 , 36, 12-7	2	30
161	Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 39-47		84
160	Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 600-8	3.2	27
159	Major depressive disorder in the general hospital: adaptation of clinical practice guidelines. <i>General Hospital Psychiatry</i> , 2003 , 25, 185-93	5.6	25
158	Identification of a novel splice-site mutation in the CYP1A2 gene. <i>British Journal of Clinical Pharmacology</i> , 2003 , 56, 341-4	3.8	42

157	Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. <i>Drug and Alcohol Dependence</i> , 2003 , 69, 205-11	4.9	33
156	Pharmacogenetics of chiral psychotropic drugs 2002 , 181-214		2
155	Therapy with Antidepressants: Pharmacogenetic Aspects 2002 , 21, 95-111		
154	Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment. <i>Chirality</i> , 2002 , 14, 347-50	2.1	4
153	Clozapine is more efficacious for tongue dystonia than olanzapine. <i>Psychopharmacology</i> , 2002 , 162, 89	4.7	7
152	The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. <i>Pharmacopsychiatry</i> , 2002 , 35, 50-6	2	59
151	In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations. <i>Molecular Psychiatry</i> , 2002 , 7, 181-8	15.1	24
150	Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. <i>International Clinical Psychopharmacology</i> , 2002 , 17, 141-3	2.2	88
149	Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 567-9	3.2	6
148	Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 211-5	1.7	59
147	Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. <i>European Neuropsychopharmacology</i> , 2002 , 12, 255-60	1.2	41
146	Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. <i>European Neuropsychopharmacology</i> , 2002 , 12, 433-44	1.2	63
145	Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 1153-93	6.2	406
144	Pharmakokinetik und therapeutisches Monitoring von Antidepressiva 2002 , 37-50		
143	Pathologic laughter associated with paroxetine treatment. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 231	1.7	3
142	Interaction of psychotropic drugs with monoamine oxidase in rat brain. <i>Journal of Pharmacy and Pharmacology</i> , 2001 , 53, 1125-30	4.8	8
141	An alternative to interruption of treatment in recurrent clozapine-induced severe neutropenia. <i>British Journal of Psychiatry</i> , 2001 , 179, 180	5.4	26
140	Enantiomeric antidepressant drugs should be considered on individual merit. <i>Human Psychopharmacology</i> , 2001 , 16, S85-S92	2.3	20

139	Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. <i>Pharmacopsychiatry</i> , 2001 , 34, 119-27	2	31
138	In vitro metabolism of citalopram by monoamine oxidase B in human blood. <i>European Neuropsychopharmacology</i> , 2001 , 11, 75-8	1.2	11
137	Lithium augmentation in venlafaxine-refractory depression. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 242-3	1.7	5
136	Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 228-31	3.2	20
135	Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 553-5	3.2	49
134	Cytochrome P450 2D6 genotype and methadone steady-state concentrations. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 229-34	1.7	86
133	Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 330-4	1.7	48
132	Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations. <i>Journal of Nervous and Mental Disease</i> , 2001 , 189, 798-9	1.8	1
131	Cytochrome P-450 activities in human and rat brain microsomes. <i>Brain Research</i> , 2000 , 855, 235-43	3.7	66
130	Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. <i>International Journal of Neuropsychopharmacology</i> , 2000 , 3, 55-60	5.8	17
129	Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. <i>Pharmacopsychiatry</i> , 2000 , 33, 112-5	2	25
128	Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. <i>Drug and Alcohol Dependence</i> , 2000 , 61, 47-54	4.9	90
127	P02.271 Pharmacokinetic drug interaction potential of risperidone as assessed by the dextromethorphan, the caffeine and the mephenytoin test. <i>European Psychiatry</i> , 2000 , 15, 394s-395s	6	
126	P01.174 Rapid remission of depression after carbamazepine augmentation of venlafaxine. <i>European Psychiatry</i> , 2000 , 15, 367s-367s	6	1
125	Efavirenz decreases methadone blood concentrations. <i>Aids</i> , 2000 , 14, 1291-2	3.5	38
124	Serotonin syndrome after small doses of citalopram or sertraline. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 713-4	1.7	12
123	Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 209-14	3.2	44
122	Inappropriate antidiuretic hormone secretion and rhabdomyolysis associated with citalopram. <i>Therapie</i> , 2000 , 55, 651-2	3.8	10

121	Psychotropic drug prescription in a psychiatric university hospital. <i>Pharmacopsychiatry</i> , 1999 , 32, 29-37	2	29
120	Olanzapine for mixed episodes of bipolar disorder. <i>Journal of Psychopharmacology</i> , 1999 , 13, 198	4.6	13
119	Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. <i>Brain Research</i> , 1999 , 831, 229-36	3.7	65
118	Oral and intravenous methadone use: some clinical and pharmacokinetic aspects. <i>Drug and Alcohol Dependence</i> , 1999 , 55, 137-43	4.9	15
117	The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 55-60		94
116	Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 166-70	3.2	22
115	Pharmacokinetic consequences of a citalopram treatment discontinuation. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 263-6	3.2	6
114	Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. <i>Biochemical Pharmacology</i> , 1998 , 56, 15-23	6	75
113	A double-blind double-dummy study of citalopram comparing infusion versus oral administration. <i>Journal of Affective Disorders</i> , 1998 , 49, 203-10	6.6	25
112	Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. <i>Biomedical Applications</i> , 1998 , 719, 234-8		54
111	Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. <i>Journal of Chromatographic Science</i> , 1998 , 36, 365-71	1.4	96
110	Multiple and simultaneous phenotyping tests: beware of ascorbic acid when determining the mephenytoin (S)/(R) ratio. <i>Clinica Chimica Acta</i> , 1998 , 271, 105-7	6.2	
109	An automated procedure for the determination of protein concentration in subcellular fractions. <i>Clinica Chimica Acta</i> , 1998 , 273, 89-93	6.2	2
108	The serotonin paradox: Negative symptoms and SSRI augmentation. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998 , 2, 19-26	2.4	11
107	Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. <i>Pharmacopsychiatry</i> , 1998 , 31, 72	2	17
106	Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. <i>American Journal of Psychiatry</i> , 1998 , 155, 499-504	11.9	233
105	Care of depression in the elderly: comparative pharmacokinetics of SSRIs. <i>International Clinical Psychopharmacology</i> , 1998 , 13 Suppl 5, S35-43	2.2	19
104	Characteristics of Psychotropic Drug Metabolism in Geriatric Patients 1998 , 13, 159-170		1

103	High interindividual variability of methadone enantiomer blood levels to dose ratios. <i>Archives of General Psychiatry</i> , 1998 , 55, 89-90		49
102	Steady state concentrations of the enantiomers of mianserin and desmethylnianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 7-13	3.2	21
101	The effect of the N-methyl-D-aspartate receptor antagonist dextromethorphan on perioperative brain injury in children undergoing cardiac surgery with cardiopulmonary bypass: results of a pilot study. <i>Neuropediatrics</i> , 1997 , 28, 191-7	1.6	20
100	Determination of the Enantiomers of Mianserin and its Metabolites in Plasma by Capillary Electrophoresis After Liquid-Liquid Extraction and On-Column Sample Preconcentration. <i>Journal of Chromatographic Science</i> , 1997 , 35, 315-320	1.4	21
99	Long-term treatment of depression: is there a use for depot antidepressants?. <i>International Clinical Psychopharmacology</i> , 1997 , 12, 77-80	2.2	4
98	Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 1-10		100
97	S.03.01 Advantages and disadvantages of lithium augmentation. <i>European Neuropsychopharmacology</i> , 1997 , 7, S82	1.2	
96	P.1.010 MAO-A and MAO-B differ in their stereoselective biotransformation of citalopram in human liver. <i>European Neuropsychopharmacology</i> , 1997 , 7, S137-S138	1.2	
95	Antidepressant treatment before hospitalization for major depression: often prescribed, often undertitrated. <i>Pharmacological Research</i> , 1997 , 35, 33-6	10.2	3
94	The association carbamazepine-mianserin in opiate withdrawal: a double blind pilot study versus clonidine. <i>Pharmacological Research</i> , 1997 , 35, 451-6	10.2	27
93	Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17, 113-7	1.7	58
92	Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. <i>Pharmacopsychiatry</i> , 1996 , 29, 108-10	2	33
91	Treatment-resistant schizophrenia: clinical experience with new antipsychotics. <i>European Neuropsychopharmacology</i> , 1996 , 6 Suppl 2, S21-5	1.2	25
90	Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 1996 , 50, 385-9	2.8	74
89	Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. <i>Clinical Pharmacokinetics</i> , 1996 , 31, 444-69	6.2	159
88	Inappropriate secretion of antidiuretic hormone and SSRIs. <i>British Journal of Psychiatry</i> , 1996 , 169, 524-5	5.4	17
87	Pharmacology and pharmacokinetics of citalopram and other SSRIs. <i>International Clinical Psychopharmacology</i> , 1996 , 11 Suppl 1, 5-11	2.2	72
86	Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. <i>Neuropsychopharmacology</i> , 1996 , 14, 253-63	8.7	85

85	Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. <i>Psychopharmacology</i> , 1996 , 128, 421-5	4.7	56
84	Caffeine consumption in hospitalized psychiatric patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1996 , 246, 83-92	5.1	51
83	Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , 1996 , 682, 265-72		67
82	Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 322-31	6.1	56
81	Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. <i>Biomedical Applications</i> , 1996 , 686, 51-63		63
80	A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 307-14	1.7	124
79	Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 570-2	3.2	30
78	Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. <i>Biomedical Applications</i> , 1995 , 669, 271-9		36
77	Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: a case report. <i>Biological Psychiatry</i> , 1995 , 38, 404-6	7.9	3
76	Reversible neutropenia during a cold: possible involvement of risperidone? A case report. <i>European Neuropsychopharmacology</i> , 1995 , 5, 1-2; discussion 3	1.2	7
75	Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. <i>Pharmacological Research</i> , 1995 , 31, 347-53	10.2	56
74	Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. <i>International Clinical Psychopharmacology</i> , 1995 , 10 Suppl 1, 15-21	2.2	74
73	Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. <i>Therapeutic Drug Monitoring</i> , 1995 , 17, 273-9 ^{3.2}		111
72	Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. <i>Chirality</i> , 1995 , 7, 389-95	2.1	65
71	Citalopram-lithium combination treatment of elderly depressed patients: A pilot study. <i>International Journal of Geriatric Psychiatry</i> , 1995 , 10, 281-287	3.9	16
70	Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994 , 57, 333-9	5.5	30
69	Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients. <i>Chirality</i> , 1994 , 6, 555-63	2.1	19
68	Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , 1994 , 652, 97-103		6

67	Levomepromazine is a substrate of cytochrome CYP2D6?. <i>European Neuropsychopharmacology</i> , 1994 , 4, 370	1.2	
66	Increased trimipramine plasma levels during fluvoxamine comedication. <i>European Neuropsychopharmacology</i> , 1994 , 4, 15-20	1.2	28
65	Influence of amesergide treatment on the dextromethorphan test. <i>British Journal of Clinical Pharmacology</i> , 1994 , 38, 151-2	3.8	0
64	Probable metabolic interaction between methadone and fluvoxamine in addict patients. <i>Therapeutic Drug Monitoring</i> , 1994 , 16, 42-5	3.2	70
63	Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs. <i>Nordic Journal of Psychiatry</i> , 1993 , 47, 13-19	2.3	10
62	Orosomuroid System: 17 Additional Orosomuroid Variants and Proposal for a New Nomenclature. <i>Vox Sanguinis</i> , 1993 , 64, 47-55	3.1	21
61	Determination of plasma levels of citalopram and its demethylated and deaminated metabolites by gas chromatography and gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , 1993 , 616, 221-8		34
60	Artifacts in the analysis of thioridazine and other neuroleptics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1993 , 11, 451-7	3.5	19
59	Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. <i>European Journal of Clinical Pharmacology</i> , 1993 , 44, 403-5	2.8	29
58	Orosomuroid system: 17 additional orosomuroid variants and proposal for a new nomenclature. <i>Vox Sanguinis</i> , 1993 , 64, 47-55	3.1	31
57	Genetischer Polymorphismus des Metabolismus von Neuroleptika: klinische Relevanz? 1993 , 99-110		1
56	Pharmakokinetische und pharmakodynamische Interaktionen zwischen trizyklischen und serotonergen Antidepressiva im Verlauf einer Behandlung 1993 , 664-670		
55	Klinische Relevanz pharmakogenetischer Phänotypisierungen 1993 , 658-663		
54	Plasma levels of trimipramine and metabolites in four patients: determination of the enantiomer concentrations of the hydroxy metabolites. <i>Therapeutic Drug Monitoring</i> , 1992 , 14, 380-5	3.2	20
53	Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. <i>Therapeutic Drug Monitoring</i> , 1992 , 14, 1-8	3.2	63
52	Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. <i>Neuropsychobiology</i> , 1992 , 25, 214-20	4	14
51	Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 52, 350-8	6.1	90
50	Alopecia and mood stabilizers: two case reports. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992 , 242, 85-8	5.1	5

49 Allgemeine Grundlagen der Pharmakokinetik und Pharmakodynamik **1992**, 273-286

48	Clozapine as an alternative treatment for neuroleptic-induced gynecomastia. <i>American Journal of Psychiatry</i> , 1991 , 148, 392-3	11.9	3
47	Light-Induced Racemization. <i>Therapeutic Drug Monitoring</i> , 1991 , 13, 356-362	3.2	17
46	Inflammation-induced changes in expression and glycosylation of genetic variants of alpha 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. <i>Biochemical Journal</i> , 1991 , 276 (Pt 2), 343-7	3.8	45
45	Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility. <i>Pharmacopsychiatry</i> , 1991 , 24, 190-5	2	37
44	Variations in relative concentrations of variants of human alpha 1-acid glycoprotein after acute-phase conditions. <i>Clinica Chimica Acta</i> , 1991 , 203, 379-85	6.2	28
43	Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. <i>Clinical Pharmacology and Therapeutics</i> , 1990 , 47, 338-46	6.1	113
42	Clinical implications of slow sulfoxidation of thioridazine in a poor metabolizer of the debrisoquine type. <i>European Journal of Clinical Pharmacology</i> , 1990 , 39, 613-4	2.8	64
41	Pharmakokinetische Aspekte der Therapieresistenz mit Antidepressiva 1990 , 85-98		4
40	Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. <i>Pharmacopsychiatry</i> , 1989 , 22, 183-7		73
39	Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants. <i>Human Genetics</i> , 1989 , 84, 89-91	6.3	35
38	Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. <i>Journal of Pharmacy and Pharmacology</i> , 1988 , 40, 767-70	4.8	20
37	Isoelectric focusing of alpha-1 acid glycoprotein (orosomucoid) in immobilized pH-gradients with 8M urea: detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. <i>Electrophoresis</i> , 1988 , 9, 650-4	3.6	39
36	Orosomucoid (alpha-1 acid glycoprotein) phenotyping by use of immobilized pH gradients with 8 M urea and immunoblotting. A new variant encountered in a population study. <i>Human Genetics</i> , 1988 , 80, 183-5	6.3	25
35	Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1988 , 337, 220-4	3.4	21
34	GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. <i>Clinica Chimica Acta</i> , 1988 , 171, 211-22	6.2	38
33	Non-response to antidepressants: risk factors and therapeutic possibilities. <i>Pharmacopsychiatry</i> , 1988 , 21, 285-7	2	8
32	New aspects in research on blood levels and bioavailability of antidepressants. <i>Psychopathology</i> , 1986 , 19 Suppl 2, 79-84	3.4	5

31	Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline. <i>International Clinical Psychopharmacology</i> , 1986 , 1, 89-101	2.2	18
30	Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. <i>International Clinical Psychopharmacology</i> , 1986 , 1, 102-12	2.2	49
29	Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein. <i>European Journal of Clinical Pharmacology</i> , 1985 , 27, 661-6	2.8	46
28	Hydroxylated Metabolites of Amitriptyline in Rat Brain After Repeated Administration of the Parent Drug. <i>Pharmacopsychiatry</i> , 1985 , 18, 91-93	2	2
27	Transport systems and enzymes involved in the metamorphosis of tryptophan into serotonin. <i>Pharmacopsychiatry</i> , 1985 , 18, 188-92	2	5
26	N-methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients. <i>Biochemical Pharmacology</i> , 1985 , 34, 409-410	6	15
25	Evaluation of the levels of free and total amitriptyline and metabolites in the plasma and brain of the rat after long-term administration of doses used in receptor studies. <i>Psychopharmacology</i> , 1984 , 84, 489-95	4.7	25
24	Amitriptylinmetabolismus im depressiven Patienten: Pharmakogenetische Aspekte und Eiweißbindung im Plasma 1984 , 298-305		2
23	Relationships between brain concentrations of desipramine and paradoxical sleep inhibition in the rat. <i>Journal of Neural Transmission</i> , 1983 , 56, 105-16	4.3	22
22	The fate of amitriptyline and its metabolites, taking into account their binding in plasma 1983 , 227-237		1
21	Quality control of amitriptyline and nortriptyline plasma level assessments: a multicenter study. <i>Pharmacopsychiatry</i> , 1982 , 15, 156-60	2	3
20	Increase of alpha 1-acid glycoprotein after treatment with amitriptyline. <i>British Journal of Clinical Pharmacology</i> , 1982 , 14, 102-3	3.8	25
19	On the relationship between free plasma and saliva amitriptyline and nortriptyline. <i>International Pharmacopsychiatry</i> , 1982 , 17, 136-46		14
18	Microprocedure to determine the polymorphic forms of acid alpha 1-glycoprotein in plasma. <i>Biomedical Applications</i> , 1982 , 229, 319-25		12
17	Effects of chronic neuroleptic therapy on human PRL secretion and testicular function. <i>Archives of Andrology</i> , 1981 , 6, 219-28		1
16	Relationship between plasma-levels of chlorpromazine and effects on EEG and evoked potentials in healthy volunteers. <i>Pharmacopsychiatry</i> , 1981 , 14, 199-204	2	11
15	Distribution of tryptophan in erythrocytes, leukocytes and thrombocytes, and its binding to plasma albumin. <i>Journal of Neural Transmission Supplementum</i> , 1979 , 165-76		2
14	The influence of oral tryptophan on cortical evoked responses in normals and schizophrenics. <i>Journal of Neural Transmission Supplementum</i> , 1979 , 177-88		

13	Neuroendocrine effects of chronic neuroleptic therapy in male psychiatric patients. <i>Psychoneuroendocrinology</i> , 1978 , 3, 245-52	5	9
12	Lithium concentrations in saliva, plasma and red blood cells of patients given lithium acetate. <i>Acta Psychiatrica Scandinavica</i> , 1978 , 58, 67-79	6.5	18
11	The analysis of free tryptophan in human blood with the Ultrafiltrator: a comparison with other methods. <i>Clinica Chimica Acta</i> , 1977 , 76, 223-31	6.2	19
10	Insulin coma therapy: decrease of plasma tryptophan in man. <i>Journal of Neural Transmission</i> , 1976 , 39, 309-13	4.3	4
9	Micro-determination of SiO ₂ , TiO ₂ , total iron (Fe ₂ O ₃), P ₂ O ₅ and F in silicates by automatic solution photometry. <i>Fresenius Zeitschrift für Analytische Chemie</i> , 1975 , 277, 359-368		6
8	Metabolism of 5-hydroxytryptophan-14c after intracisternal injection with and without the influence of drugs in the rat brain. <i>Psychopharmacology</i> , 1975 , 45, 39-45	4.7	4
7	Quantitative determination of indolic compounds in the rat brain using p-dimethylaminocinnamaldehyde as reagent. <i>Journal of Chromatography A</i> , 1975 , 109, 313-24	4.5	7
6	Determination of free and bound plasma tryptophan by ultrafiltration. <i>Clinica Chimica Acta</i> , 1974 , 51, 35-40	6.2	16
5	Identification of N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine and bufotenin by cellulose TLC. <i>Journal of Chromatography A</i> , 1973 , 86, 269-73	4.5	11
4	Influence of progesterone on norepinephrine metabolism of the rat brain in connection with amphetamine and stress. <i>Neuroendocrinology</i> , 1971 , 7, 16-24	5.6	7
3	Separation of indole derivatives and catecholamines by thin-layer chromatography. <i>Journal of Chromatography A</i> , 1971 , 59, 463-6	4.5	11
2	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents 319-328		
1	Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with l- and d,l-methadone. <i>World Journal of Biological Psychiatry</i> , 1-10	3.8	4